The Effect of VTC-G15 (a Pentapeptide Cleavage Product og GLP-1) on Whole Body Glucose Metabolism in Man (LVKGR)

Elahi, Dariush, PhD

Status and phase: Unknown; Phase 1

Conditions: Insulin Resistance

Treatments: Drug: Last 5 amino acids of GLP-1; Drug: placebo saline

Study type: Interventional

Funder types: Other; Industry; NIH

Identifiers

NCT02518932

VTC-G15

Details and patient eligibility

About

To asses the modulating properties of the cleaved pentapeptide product of GLP-1 amide.

Full description

The investigators have previously demonstrated that infusion of the pentapeptide during hyperglycemic clamps in dogs significantly increases the glucose infusion rate necessary to maintain stable hyperglycemia without any significant differences in insulin or glucagon secretion. The present study's aim is to examine whether this also occurs in humans. It may be necessary to examine a dose response curve. Specifically, in twenty healthy volunteers glucose infusion rate during the peptide infusion will be compared to the glucose infusion rate during saline administration during a 4 hour hyperglycemic clamp, in a cross over design(mg/kg/min).

Enrollment: 20 estimated patients

Sex: All

Ages: 18 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• BMI 18.5-25;
• 33-38

Exclusion criteria

• T2D
• T1D
• Hypoglycemic agents

Trial design

Primary purpose: Supportive Care

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Single Blind

---

20 participants in 2 patient groups, including a placebo group

Drug GLP-1 (32-36) Amide

Experimental group

Description:

To examine insulinomemtic of the last 5 amino acids of GLP-1 from 60-180 min during a 4 hour hyperglycemic clamp

Treatment:

Drug: Last 5 amino acids of GLP-1

Placebo

Placebo Comparator group

Description:

To examine the effect of saline on glucose uptake

Treatment:

Drug: placebo saline